Atraverse is a medical device startup company formed in the Summer of 2022 and founded by the same co-founders of FARAPULSE (acquired for up to $800M by Boston Scientific in the Summer of 2021). In January 2023, Atraverse closed a $5M Seed I round. In October 2023, NuFund Venture Group agreed to lead the Seed II round up to $3M and just closed their investment. We are now seeking syndicate investors to join NuFund Venture Group and other prior investors including New York Angels and HBS Angels of NYC plus multiple key-opinion leading physicians in the cardiac electrophysiology arena who have also invested to date. Atraverse Medical is a left-heart access company and fast follower to Baylis Medical, which was acquired by Boston Scientific for $1.75B cash at close (an ~18x trailing twelve month revenue multiple)! The Baylis Versacross product is our predicate device, and Atraverse follows a Class II, 510(k) regulatory pathway, reinforced by the Versacross 510(k) filing obtained via the FOI act request we submitted earlier this year. Atraverse Medical is on track to submit our 510(k) filing for our proprietary "Hotwire" device to the FDA by the end January 2024, with FDA 510(k) clearance anticipated in the April/May 2024 timeframe and initial sales targeted by Q3 2024 with identified launch customers. This is an opportunity for angel investors to get into the deal before we turn our focus to institutional investors for a $10M Series A Financing in 2024 after achieving these key regulatory, commercial, and other value-adding milestones! Atraverse Medical is led by an industry-experienced leadership team with the right expertise to commercialize the 'best-in-class' left heart access tool and to capitalize on a lucrative strategic acquisition within 3-5 years. CEO/Co-Founder, John Slump, prior co-founder of FARAPULSE, more recently served as CFO of medical device startup, Surgical Innovation Associates, where John sourced $25M of start-up capital and helped grow the company from $0 to $10M in annual revenue, culminating in an acquisition in Dec. 2022 by Integra Life Sciences for up to $140M. Co-Founder/CTSO, Dr. Steven Mickelsen, is a cardiac electrophysiologist, inventor of the FARAPULSE, and more recently, co-inventor of the Atraverse technology, and currently practices medicine at Scripps in San Diego. Co-Founder/COO, Eric Sauter, is an engineer by trade, was employee #1 at FARAPULSE, and has served in multiple other cardiac device R&D and manufacturing engineering roles and is the co-inventor of the Atraverse technology with Dr. Mickelsen. We have also recruited VP Marketing, Jay Kelley, and VP Regulatory/Quality, Charles Yang, who bring over 20 years of medical device R&D, engineering, marketing, quality, and regulatory experience with cardiac devices and worked together at a prior device startup, Ablation Frontiers, which was acquired by Medtronic for a deal valued up to $220 million. We hope you will join our growing investor syndicate!
